PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Compl te if Kn wn Substitute for form 1449/PTO **Application Number** Filing Date 12/29/03

-	TION DISCLUSURE	First Named Inventor Stephen Eliot	Zweig
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	
		Examiner Name	
Sheet 1	of 1	Attorney Docket Number	
	· · · · · · · · · · · · · · · · · · ·		

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (V known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,389,217		•	
		US- 5,313,848			
		US- 5.667.303			
		^{US-} 6,217,213			
		^{US-} 6,544,925			
		^{US-} 6,629,057			
		^{US-} Re 36,200			
		US-			
		US-			
		US-			
	İ	US-			
		US-			

FOREIGN PATENT DOCUMENTS						
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		WIPO WO0125472A1				
						L

Examiner	 Date	
Signature	Considered	
_		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
			Application Number		
INFORMA	TION DIS	CLOSURE	Filing Date	12/29/03	
STATEMENT BY APPLICANT			First Named Inventor	Stephen Eliot Zweig	
(Use as many sheets as necessary)			Art Unit		
			Examiner Name		
Sheet 1	of	1	Attorney Docket Number		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Rosenberg, Immunogenicity of Biological Therapeutics, A Hierarchy of Concerns, Dev. Biol. Basel, Karger 2003, Vol 112, pp15-21	
		Chamberlain, "Immunogenicity of Therapeutic Proteins", The Regulatory Review 5:5, August 2002,, pp 4-9	
		Hochuli, "Interferon Immunogenicity: Technical Evaluation of Interferon •2•", J. Interferon and Cytokine Res. 17 supplement 1: S15-S21, 1997	
		DePaolis et. al., "Characterization of erythropoietin dimerization", J Pharm Sci. 1995 Nov;84(11):1280-4	
		Haselbeck, "Epoetins: differences and their relevance to immunogenicity", Current Medical Research and Opinions 19(5), p 430-432 (2003)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.